285 related articles for article (PubMed ID: 30931851)
41. Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment.
Kotur N; Lazic J; Ristivojevic B; Stankovic B; Gasic V; Dokmanovic L; Krstovski N; Milosevic G; Janic D; Zukic B; Pavlovic S
Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32344632
[TBL] [Abstract][Full Text] [Related]
42. Association between MTHFR microRNA binding site polymorphisms and methotrexate concentrations in Chinese pediatric patients with acute lymphoblastic leukemia.
Wang SM; Zeng WX; Wu WS; Sun LL; Yan D
J Gene Med; 2017 Nov; 19(11):353-359. PubMed ID: 28990296
[TBL] [Abstract][Full Text] [Related]
43. Effects of a microRNA binding site polymorphism in SLC19A1 on methotrexate concentrations in Chinese children with acute lymphoblastic leukemia.
Wang SM; Sun LL; Zeng WX; Wu WS; Zhang GL
Med Oncol; 2014 Jul; 31(7):62. PubMed ID: 24927955
[TBL] [Abstract][Full Text] [Related]
44. Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy.
Inoue K; Yuasa H
Drug Metab Pharmacokinet; 2014; 29(1):12-9. PubMed ID: 24284432
[TBL] [Abstract][Full Text] [Related]
45. Do polymorphisms in ABC transporter genes influence risk of childhood acute lymphoblastic leukemia?
Jamroziak K; Robak T
Leuk Res; 2008 Aug; 32(8):1173-5. PubMed ID: 18294687
[TBL] [Abstract][Full Text] [Related]
46. Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients.
Wang Z; Zhang N; Chen C; Chen S; Xu J; Zhou Y; Zhao X; Cui Y
Curr Drug Metab; 2019; 20(7):592-600. PubMed ID: 31267867
[TBL] [Abstract][Full Text] [Related]
47. Effects of
Yang FF; Xue TL; Gao C; Wu Y; Lin W; Li J; Zhang RD; Zheng HY; Liu SG
Pharmacogenomics; 2022 Oct; 23(15):821-834. PubMed ID: 36193736
[No Abstract] [Full Text] [Related]
48. Pharmacogenetic aspects of efficacy and safety of methotrexate treatment in pediatric acute lymphoblastic leukemia.
Gurieva OD; Savelyeva MI; Valiev TT; Sozaeva ZA; Kondratenko SN; Ilyin MV
Drug Metab Pers Ther; 2023 Dec; 38(4):349-357. PubMed ID: 38098143
[TBL] [Abstract][Full Text] [Related]
49. The effects of drug transporters on the efficacy of methotrexate in the treatment of rheumatoid arthritis.
Gao J; Wang C; Wei W
Life Sci; 2021 Mar; 268():118907. PubMed ID: 33428880
[TBL] [Abstract][Full Text] [Related]
50. The role of ABC-transporter gene polymorphisms in chemotherapy induced immunosuppression, a retrospective study in childhood acute lymphoblastic leukaemia.
Erdélyi DJ; Kámory E; Zalka A; Semsei AF; Csókay B; Andrikovics H; Tordai A; Borgulya G; Magyarosy E; Galántai I; Fekete G; Falus A; Szalai C; Kovács GT
Cell Immunol; 2006 Dec; 244(2):121-4. PubMed ID: 17434155
[TBL] [Abstract][Full Text] [Related]
51. In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile.
Sorich MJ; Pottier N; Pei D; Yang W; Kager L; Stocco G; Cheng C; Panetta JC; Pui CH; Relling MV; Cheok MH; Evans WE
PLoS Med; 2008 Apr; 5(4):e83. PubMed ID: 18416598
[TBL] [Abstract][Full Text] [Related]
52. Methylation analysis of the SLC19A1 promoter region in Chinese children with acute lymphoblastic leukaemia.
Wang SM; Li M; Wu WS; Sun LL; Yan D
J Clin Pharm Ther; 2020 Aug; 45(4):646-651. PubMed ID: 32403197
[TBL] [Abstract][Full Text] [Related]
53. Association between SLCO1A2 genetic variation and methotrexate toxicity in human rheumatoid arthritis treatment.
Wang J; Yin J; Li W; Xiao C; Han J; Zhou F
J Biochem Mol Toxicol; 2020 Aug; 34(8):e22513. PubMed ID: 32304147
[TBL] [Abstract][Full Text] [Related]
54. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.
Maiguma T; Hayashi Y; Ueshima S; Kaji H; Egawa T; Chayama K; Morishima T; Kitamura Y; Sendo T; Gomita Y; Teshima D
Int J Clin Pharmacol Ther; 2008 Nov; 46(11):584-90. PubMed ID: 19000557
[TBL] [Abstract][Full Text] [Related]
55. Novel and replicated clinical and genetic risk factors for toxicity from high-dose methotrexate in pediatric acute lymphoblastic leukemia.
Zobeck M; Bernhardt MB; Kamdar KY; Rabin KR; Lupo PJ; Scheurer ME
Pharmacotherapy; 2023 Mar; 43(3):205-214. PubMed ID: 36764694
[TBL] [Abstract][Full Text] [Related]
56. Correlation between methylation level of the
Huang X; Hao Q; Fang Q; Zhang P; Wei H; Wang Y; Wang J; Mi Y
Pharmacogenomics; 2023 Apr; 24(5):261-268. PubMed ID: 36999405
[No Abstract] [Full Text] [Related]
57. Effect of SLCO1B1 Polymorphisms on High-Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma.
Schulte RR; Choi L; Utreja N; Van Driest SL; Stein CM; Ho RH
Clin Transl Sci; 2021 Jan; 14(1):343-353. PubMed ID: 32961024
[TBL] [Abstract][Full Text] [Related]
58. The effect of ABCG2 and ABCC4 on the pharmacokinetics of methotrexate in the brain.
Sane R; Wu SP; Zhang R; Gallo JM
Drug Metab Dispos; 2014 Apr; 42(4):537-40. PubMed ID: 24464805
[TBL] [Abstract][Full Text] [Related]
59. Association of GGH Promoter Methylation Levels with Methotrexate Concentrations in Chinese Children with Acute Lymphoblastic Leukemia.
Wang SM; Kong XY; Li M; Sun LL; Yan D
Pharmacotherapy; 2020 Jul; 40(7):614-622. PubMed ID: 32476160
[TBL] [Abstract][Full Text] [Related]
60. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
